View More Recent Stories
-
Gilead Sciences (GILD) PT Bumped to $98 at BMO Capital Posts Q2, Remains Sidelined
-
Gilead Sciences (GILD) Epclusa Approval Secures Near-Term HCV Dominance - BMO Capital
-
Gilead Sciences (GILD) Needs M&A to Fill the Gap Following HCV Miss - BMO Capital
-
BMO Capital Starts Gilead Sciences (GILD) at Market Perform
-
Notable Analyst Rating Changes 2/5: (GS) (ALL) (ABT) Upgraded; (LNKD) (KSS) (LINE) Downgraded
-
Hillary Clinton All Bark, No Bite with Biotech Tweet
-
Gilead Sciences (GILD) Bullish Stance Reiterated at BMO Capital Amid 'Strong' Q1
-
Streetinsider.com's Hot Lunchtime Reads 4/23: (GILD) (FB) (ABBV) (HLF)
-
Abbvie (ABBV) Weakness Related to Hep-C Data from Gilead (GILD), BMO Capital Says
-
Positive Read-Through for Gilead Sciences (GILD) from ABBV/PCYC Deal
-
Streetinsider.com's Hot Lunchtime Reads 12/22: (GILD) (CUBA) (VHC) (ACHN)
-
Buy Gilead Sciences (GILD) on Weakness, BMO Capital Says; PT Dropped $20 on News
-
AbbVie's (ABBV) VIEKIRA PAK Seen as Limited Threat to Gilead's (GILD) HCV Dominance, BMO Capital Says
-
Gilead Sciences (GILD) PT Lifted to $165 at BMO Capital on Strong Q2
-
Streetinsider.com's Hot Lunchtime Reads 03/31: (ISIS) (IMAX) (TSLA) (GILD)
-
Stocks Weaker, Led by High-Beta Names
-
Shares of Gilead Sciences (GILD) Gain Back Majority of Acquisition Dip
-
BMO Capital Upgrades Gilead Sciences (GILD) to Outperform
-
BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform
-
Notable Analyst Rating Changes 11/16: CAT, CREE, S, BRCD Upgraded; NLST, BUCY, PWRD, JOYG Downgraded
-
Gilead Sciences (GILD) volatility flat, shares near four year low
-
Notable Analyst Rating Changes 4/22: F, CAT, BRCD, FDX Upgraded; NBR, CCO, HAL, WFR, FITB Downgraded
-
BMO Upgrades Gilead (GILD) to Outperform
-
Notable Analyst Rating Changes 7/18: C, SPWR, XTO, UAUA Upgraded; VCLK, GILD, MER, BBY Downgraded
-
David Moenning's Daily State of the Markets: 7/18
-
BMO Capital Downgrades Gilead Sciences (GILD) to Market Perform
-
BMO Downgrades Gilead Sciences (GILD) to Market Perform

